Theradiag

Theradiag's Lisa Tracker monitoring kits will be referenced in supply contracts for Merck's immunosuppressant drug.

The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products. 

The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.

NEW YORK (GenomeWeb News) – Diagnostic firm Theradiag today announced a partnership with French organizations to develop diagnostic and theranostic tools for rheumatoid arthritis.

NEW YORK (GenomeWeb News) – French molecular diagnostics firm Theradiag announced Monday that its microRNA diagnostics subsidiary Prestizia has inked two deals to develop HIV/AIDS assays in collaboration with the French National Center for Scientific Research (CNRS).

Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Theradiag this week announced several management changes in line with the strategic organization of the company into two divisions following last year's acquisition of microRNA technology firm Prestizia.

NEW YORK (GenomeWeb News) – French theranostics and IVD firm Theradiag will distribute Luminex's xTAG RVP and xTAG GPP assays in France, the companies said recently.

NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.

After buying small microRNA firm Prestizia last June, France's Theradiag is moving forward in development of several miRNA tests in the HIV disease area, as well as two companion diagnostic projects for experimental therapies, one for HIV and another for obesity under a $1.6 mill

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.